January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
January 2026 in “Journal of Investigative Dermatology” Female-pattern hair loss may involve an autoimmune-like process, suggesting new treatment options.
Deuruxolitinib is approved to treat severe alopecia areata in adults.
January 2026 in “Dermatologic Therapy” Folliculotropic Mycosis Fungoides requires stage-based treatment, with early stages using skin therapies and advanced stages needing aggressive treatments.
December 2025 in “IP Indian Journal of Clinical and Experimental Dermatology” Androgenetic alopecia in males is linked to significant psychological distress, highlighting the need for both mental and dermatological care.
December 2025 in “International Journal of Dermatology and Venereology” Targeted immunotherapies may offer better treatment for alopecia areata by controlling inflammation and immune responses.
December 2025 in “International Journal of Surgery” GBP1 is a key target for treating Epstein-Barr virus-related kidney cancer, and finasteride may help.
Stress can cause hair loss and trigger autoimmunity by damaging hair follicle cells.
November 2025 in “Trends in Immunotherapy” Exosomes from certain cells can improve hair regrowth by changing the immune response.
November 2025 in “The Journal of Immunology” The S1PR 1&4 modulator may effectively treat alopecia areata by reducing hair loss and immune cell activity.
Thymoma with alopecia areata may be linked to abnormal immune cells.
August 2025 in “Dermatology and Therapy” Alopecia areata involves specific gene changes and immune pathways, offering new treatment targets.
July 2025 in “Journal of Investigative Dermatology” Immune system changes may contribute to female pattern hair loss.
July 2025 in “Journal of Investigative Dermatology” Scarring alopecia involves increased immune cells and specific gene changes near damaged hair follicles.
July 2025 in “Journal of Investigative Dermatology” Enhancing Tregs can protect against alopecia areata.
July 2025 in “Journal of Investigative Dermatology” Monocyte-derived dendritic cells play a key role in UVB-induced skin sensitivity and inflammation.
Alopecia areata involves immune system changes, especially in severe cases, with potential new treatment targets identified.
June 2025 in “Academic Medical Journal” Restoring hair follicle immune privilege may help treat alopecia areata.
May 2025 in “Frontiers in Pharmacology” Targeting gut microbiome and metabolome may help treat autoimmune skin diseases like alopecia areata.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Linoleic acid and magnesium are key in alopecia areata progression, and tofacitinib can help by affecting their pathway.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Targeting specific metabolic and ionic pathways may improve alopecia areata treatment.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Linoleic acid and magnesium are key in alopecia areata progression, and tofacitinib can help by affecting their pathway.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Targeting specific metabolic and ionic pathways may improve alopecia areata treatment.
May 2025 in “Nonlinear Analysis Real World Applications” Reducing CD8+ T cell growth can stabilize alopecia areata.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
February 2025 in “International Journal of Molecular Sciences” RIPK1 inhibitors may help prevent alopecia areata by reducing immune cell activity.
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Mogamulizumab can cause hair loss, often linked to a better treatment response.
January 2025 in “Clinical Cosmetic and Investigational Dermatology” Pediatric alopecia areata is more immune-active than adult cases, suggesting age-specific treatments and potential use of JAK inhibitors.
January 2025 in “Journal of Case Reports and Scientific Images” Early diagnosis and treatment are crucial for managing Folliculotropic Mycosis Fungoides on the scalp.